1. 1730. Outcomes of Patients With Detectable Cytomegalovirus (CMV) DNA at Randomization in the Double-blind, Placebo-Controlled Phase 3 Trial of Letermovir (LET) Prophylaxis for CMV-Seropositive Allogeneic Hematopoietic-Cell Transplantation (HCT) Recipients. (26th November 2018) Authors: Marty, Francisco M; Ljungman, Per; Chemaly, Roy F; Wan, Hong; Teal, Valerie L; Butterton, Joan; Yeh, Wendy W; Leavitt, Randi Y; Badshah, Cyrus Journal: Open forum infectious diseases Issue: Volume 5(2018)Supplement 1 Page Start: S56 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 502. Early COVID-19 Treatment with SARS-CoV-2 Neutralizing Antibody Sotrovimab. (4th December 2021) Authors: Gupta, Anil K; Rojas, Yaneicy Gonzalez; Juarez, Erick; Casal, Manuel Crespo; Moya, Jaynier; Falci, Diego Rodrigues; Sarkis, Elias H; Solis, Joel; Zheng, Hanzhe; Scott, Nicola; Cathcart, Andrea L; Hebner, Christy; Sager, Jennifer; Mogalian, Erik; Austin, Daren; Peppercorn, Amanda; Alexander, Eliza... Journal: Open forum infectious diseases Issue: Volume 8(2021)Supplement 1 Page Start: S353 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label trials. (November 2017) Authors: Lawitz, Eric; Buti, Maria; Vierling, John M; Almasio, Piero L; Bruno, Savino; Ruane, Peter J; Hassanein, Tarek I; Muellhaupt, Beat; Pearlman, Brian; Jancoriene, Ligita; Gao, Wei; Huang, Hsueh-Cheng; Shepherd, Aimee; Tannenbaum, Brynne; Fernsler, Doreen; Li, Jerry J; Grandhi, Anjana; Liu, Hong; Su... Journal: Lancet gastroenterology and hepatology Issue: Volume 2:Number 11(2017) Page Start: 814 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials. (November 2017) Authors: Gane, Edward J; Pianko, Stephen; Roberts, Stuart K; Thompson, Alexander J; Zeuzem, Stefan; Zuckerman, Eli; Ben-Ari, Ziv; Foster, Graham R; Agarwal, Kosh; Laursen, Alex L; Gerstoft, Jan; Gao, Wei; Huang, Hsueh-Cheng; Fitzgerald, Brian; Fernsler, Doreen; Li, Jerry J; Grandhi, Anjana; Liu, Hong; Su,... Journal: Lancet gastroenterology and hepatology Issue: Volume 2:Number 11(2017) Page Start: 805 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗